SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed7d 15h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The wider-than-expected loss and higher cash burn reflect the ramp-up of the pivotal trial. The key catalyst is the FORTIFI-HN01 interim analysis in mid-2027. Monitor enrollment updates and any early efficacy signals from the FORTIFI-FLEX dosing study.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$9.98
T+0 close · Nov 9, 2026 · via day close
Latest settled
−2.30%
T+5 · $9.75
Vs SPY
−0.61%
α at T+5
Next horizon
T+20
in 21d
  1. T+0 · Nov 9 $9.98entry
  2. T+1 · 7d ago +2.00%α +2.37% · $10.18
  3. T+5 · 16h ago −2.30%α −0.61% · $9.75
  4. T+20 · in 21d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Bicara Therapeutics reported Q3 2026 net loss of $71.2M ($1.04 per share), wider than the $36.3M loss a year ago, as R&D and G&A costs rose sharply to support the pivotal FORTIFI-HN01 trial. The company achieved substantial enrollment in the trial and expects interim topline data in mid-2027. Cash of $442.3M is expected to fund operations into H1 2029.

Key Financial Metrics

EPS
−$1.04
est −$0.86 · -20.9%
Revenue
$0.00
est $0.00
Rating
miss

Key Facts

  • Net loss of $71.2M in Q3 2026 vs $36.3M in Q3 2025
  • EPS of -$1.04 vs consensus -$0.86 (miss of 20.9%)
  • Revenue $0 (pre-revenue clinical-stage company)
  • Cash, cash equivalents and marketable securities $442.3M as of Sep 30, 2026
  • Cash runway into first half of 2029
  • Substantial enrollment achieved in FORTIFI-HN01 pivotal trial; interim data expected mid-2027
  • R&D expenses $56.5M in Q3 2026 vs $33.0M in Q3 2025
  • G&A expenses $19.2M in Q3 2026 vs $7.7M in Q3 2025

Financial Impact

Net loss widened to $71.2M from $36.3M; EPS -$1.04 vs consensus -$0.86; cash burn increased as trial enrollment accelerated

net lossepscashr&d expenses

Risk Factors

  • Clinical-stage company with no approved products or revenue
  • EPS miss of 20.9% vs consensus
  • Rising R&D and G&A costs may pressure cash runway if trial timelines extend
  • Interim analysis results not expected until mid-2027, leaving a long period without catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398297

Track record

26 reports on BCAX

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +5.65% at T+20 after the Apr 15, 2026 report. 1 of 3 went positive at some point.

Filters
  1. Nov 9, 20267d ago Press Release Neutral 4/10 Viewing Entry $9.98 Now $9.75 −2.30% settles Dec 8
  2. Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  3. Nov 4, 202612d ago Press Release Neutral 2/10 Entry $8.89 Now $9.75 +9.67% settles Dec 3
  4. Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $16.42 to $8.89 Now $9.75 −40.62% ▼ −45.86% −44.52% vs SPY
  5. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $17.29 to $9.13 Now $9.75 −43.61% ▼ −47.19% −44.73% vs SPY
  6. Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $22.78 to $18.35 Now $9.75 −57.20% ▼ −19.45% −18.89% vs SPY
  7. Aug 25, 202611w ago 8-K Neutral 2/10 Entry $24.73 to $19.78 Now $9.75 −60.57% ▼ −20.02% −20.24% vs SPY
  8. Aug 14, 202613w ago Press Release Neutral 2/10 Entry $24.28 to $23.20 Now $9.75 −59.84% ▼ −4.45% −2.46% vs SPY
  9. Aug 12, 202613w ago Insider Cluster Neutral Not scored Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
  10. Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $23.63 to $22.81 Now $9.75 −58.74% ▼ −3.47% −1.72% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 18m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026